Blisters from medication allergy can range from a mild nuisance to a life-threatening dermatological emergency. When the immune system reacts abnormally to a drug or its metabolites, it can trigger inflammatory pathways that damage the skin, causing fluid to accumulate between skin layers and form blisters. Certain medicines — including antibiotics, anticonvulsants, allopurinol, and DPP-4 inhibitors — are more commonly implicated. Understanding why these reactions occur, how to recognise the warning signs, and when to seek urgent NHS care can be critical in preventing serious harm.

Why Some Medications Cause Blistering Skin Reactions

Medication-induced blisters arise from immune-mediated skin damage — either T-cell cytotoxicity (as in SJS/TEN) or antibody-complement activation (as in drug-induced bullous pemphigoid) — triggered by drugs such as antibiotics, anticonvulsants, allopurinol, and DPP-4 inhibitors.

Blisters from medication allergy occur when the immune system mounts an abnormal response to a drug or one of its metabolites. Rather than tolerating the medication, the immune system identifies it as a foreign threat, triggering inflammatory pathways that damage the skin at a cellular level. This immune-mediated damage causes fluid to accumulate between layers of the skin, forming blisters — a process known as drug-induced bullous eruption.

Not all drug reactions are allergic in nature. Some are pharmacological (predictable, dose-dependent side effects), whilst others are idiosyncratic (unpredictable and not directly related to dose). Blistering reactions tend to fall into the idiosyncratic category, making them harder to anticipate.

Experiencing these side effects? Our pharmacists can help you navigate them →

It is important to distinguish between two broad types of immune mechanism:

• T-cell–mediated (cytotoxic) reactions — delayed immune responses in which T-cells directly attack skin cells. This is the predominant mechanism in severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and DRESS syndrome. Reactions typically appear days to weeks after starting a medication.

• Antibody- and complement-mediated reactions — in which circulating antibodies and complement activation target proteins within the skin. This mechanism underlies drug-induced bullous pemphigoid and linear IgA bullous dermatosis, producing tense blisters that differ clinically from SCARs.

Certain drug classes are more commonly implicated in blistering reactions. These include antibiotics (particularly penicillins and sulfonamides), anticonvulsants (such as carbamazepine and lamotrigine), non-steroidal anti-inflammatory drugs (NSAIDs), allopurinol, and some chemotherapy agents. In UK clinical practice, DPP-4 inhibitors (gliptins) — used in type 2 diabetes — are a recognised cause of drug-induced bullous pemphigoid, as highlighted in MHRA Drug Safety Updates. Vancomycin is associated with linear IgA bullous dermatosis, and immune checkpoint inhibitors (used in oncology) can also trigger bullous pemphigoid.

Genetic factors can significantly increase an individual's susceptibility. For example:

• HLA-B*5701 is associated with hypersensitivity to abacavir (screening is now standard practice before prescribing, per the abacavir SmPC)

• HLA-B*5801 is associated with allopurinol hypersensitivity syndrome

• HLA-B*1502 (in people of Han Chinese, Thai, and some other Asian ancestries) and HLA-A*31:01 are associated with carbamazepine-induced SCARs; the carbamazepine SmPC recommends screening in at-risk populations before prescribing

Understanding these mechanisms helps clinicians identify at-risk patients and make safer prescribing decisions, in line with NICE CG183 (Drug allergy: diagnosis and management).

Recognising the Signs of a Drug-Induced Blister Reaction

Key warning signs include fluid-filled blisters, painful or tender skin preceding visible blistering, mucosal involvement, and systemic features such as fever or conjunctivitis, which can precede SJS/TEN skin changes by one to three days.

Identifying blisters from medication allergy early is essential, as some reactions can escalate rapidly into life-threatening conditions. Symptoms typically develop within days to weeks of starting a new medication, although delayed reactions can occasionally occur after months of use. Any recently introduced or recently changed medication should be considered as a potential cause.

The skin changes associated with drug-induced blistering can vary considerably in appearance and distribution. Common signs include:

• Fluid-filled blisters (vesicles or bullae) on the skin or mucous membranes

• Red, inflamed, or tender skin surrounding the blisters

• Skin pain or tenderness — an early and important warning sign of SJS/TEN, often preceding visible blistering

• Skin that peels or detaches when lightly rubbed (known as a positive Nikolsky sign — this should only be assessed by a healthcare professional; patients should not attempt to test this themselves)

• Target-shaped lesions — concentric rings of redness. Classic target lesions are more typical of erythema multiforme, which is most commonly triggered by infections such as herpes simplex virus (HSV) rather than drugs. In SJS and TEN, lesions are usually atypical (flat, dusky, or necrotic) and are accompanied by more extensive skin involvement

• Widespread rash that spreads rapidly across the body

• Blistering inside the mouth, eyes, or genitals, which indicates mucosal involvement and is a serious warning sign

Early systemic features that should prompt urgent assessment include fever, sore throat, conjunctivitis (red or sticky eyes), and malaise — these can precede the skin changes in SJS/TEN by one to three days. Swollen lymph nodes and facial swelling may also occur, particularly in DRESS syndrome.

The presence of skin pain, mucosal involvement, or systemic features alongside blistering skin is a warning sign that the reaction may be severe and requires immediate medical attention.

Not every blister is caused by a drug allergy — other causes include infections (such as chickenpox or impetigo), autoimmune conditions (such as pemphigus or bullous pemphigoid), and physical trauma. However, if blistering begins or worsens after starting a new medication, a drug reaction should always be considered until proven otherwise.

Serious Conditions Linked to Medication Allergy and Blistering

Severe drug-induced blistering conditions include SJS (less than 10% BSA), TEN (more than 30% BSA, mortality up to 30%), DRESS syndrome, and fixed drug eruption; the causative medicine must be stopped immediately in suspected SJS or TEN.

Several distinct and potentially life-threatening conditions are associated with blisters from medication allergy. Recognising these by name helps patients and clinicians understand the severity of what may be occurring and act accordingly.

Stevens-Johnson Syndrome (SJS) is a severe mucocutaneous reaction characterised by blistering and erosion of the skin and mucous membranes, affecting less than 10% of the body surface area (BSA). It is most commonly triggered by medications such as allopurinol, anticonvulsants, and sulfonamide antibiotics. SJS carries a significant mortality risk and requires hospitalisation in a specialist setting.

SJS/TEN overlap describes cases where 10–30% of BSA is affected, representing an intermediate severity.

Toxic Epidermal Necrolysis (TEN) is the most severe end of the spectrum, involving detachment of more than 30% of BSA. It is a dermatological emergency with a mortality rate of up to 30%. Both SJS and TEN are managed in specialist burns units or intensive care settings in the UK. Prognosis is assessed using the SCORTEN scoring system, which guides clinical decision-making and transfer to appropriate specialist centres.

In suspected SJS or TEN, the causative medicine must be stopped immediately. Early withdrawal of the offending drug is one of the most important factors in improving outcomes. Do not wait for specialist confirmation before stopping the suspected medicine if severe features are present.

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS syndrome) is another serious condition that can include blistering alongside widespread rash, fever, lymphadenopathy, and internal organ involvement (particularly the liver, kidneys, and lungs). It typically develops 2–8 weeks after starting the causative drug — a longer latency than most other drug reactions. Diagnosis is supported by the RegiSCAR criteria, and management requires serial monitoring of liver function, renal function, and other organ parameters. The causative drug should be stopped promptly.

Fixed drug eruption is a less severe but distinctive reaction in which blistering or inflamed patches appear at the same site each time the offending drug is taken. Common culprits include NSAIDs, tetracyclines, and co-trimoxazole.

A specific note on abacavir: if abacavir hypersensitivity is suspected, the medicine must be stopped immediately and must never be re-started (re-challenged). Re-challenge can cause a rapid, potentially fatal hypersensitivity reaction, as stated in the abacavir SmPC.

Whilst these conditions are uncommon, their potential severity means that any blistering reaction following medication use should be taken seriously and assessed by a healthcare professional without delay. Further information is available on the NHS Stevens-Johnson syndrome page and through the British Association of Dermatologists (BAD).

When to Seek Urgent Medical Help in the UK

Call 999 or go to A&E immediately if blisters are spreading rapidly, skin is peeling or painful, mucous membranes are affected, or systemic features such as high fever or breathing difficulty are present.

Knowing when to escalate care is critical when dealing with blisters from medication allergy. Some reactions are mild and self-limiting, but others can deteriorate rapidly and become life-threatening within hours. Patients and carers should be aware of the key warning signs that require immediate action.

Call 999 or go to your nearest A&E immediately if you or someone else experiences:

• Rapidly spreading blisters or skin peeling over large areas of the body

• Painful or tender skin, even before blistering is visible

• Blistering or sores inside the mouth, eyes, or genitals

• Difficulty breathing, swallowing, or swollen lips and tongue (suggesting anaphylaxis)

• High fever combined with widespread skin changes

• Skin that comes away when touched or rubbed

• Confusion, dizziness, or collapse

If you experience any of the severe features listed above, stop the suspected medicine immediately and seek emergency care. If you are taking abacavir and develop any features of hypersensitivity (rash, fever, nausea, vomiting, diarrhoea, abdominal pain, or breathing difficulties), stop the medicine immediately, go to A&E, and do not restart it under any circumstances.

Not sure if this is normal? Chat with one of our pharmacists →

When attending A&E, bring all your medicines, their packaging, and a note of when each was started — this information is essential for identifying the likely cause.

Contact your GP urgently or call NHS 111 if you notice:

• New blisters appearing after starting a medication, even if mild

• A spreading rash with any systemic symptoms such as fever, sore throat, or joint pain

• Blistering that is not improving or is worsening over 24–48 hours

For reactions that do not involve the severe features above, do not stop a prescribed medication without medical advice. Abruptly discontinuing certain medications (such as anticonvulsants) can carry its own risks. A GP or pharmacist can advise on whether it is safe to continue, pause, or switch treatment whilst the reaction is being assessed. NHS 111 is available 24 hours a day and can provide guidance on the appropriate level of care needed.

Diagnosis and Treatment on the NHS

NHS diagnosis follows NICE CG183, using skin biopsy, blood tests, and specialist allergy review; severe reactions require hospital admission, with cyclosporine or etanercept increasingly used in specialist centres for SJS/TEN.

When a patient presents with suspected blisters from medication allergy, NHS clinicians will take a thorough history, focusing on all medications taken in the preceding weeks — including over-the-counter drugs, herbal remedies, and supplements. Establishing a clear timeline between drug initiation and symptom onset is central to identifying the likely causative agent, in line with NICE CG183 (Drug allergy: diagnosis and management).

Diagnostic investigations may include:

• Skin biopsy — to examine the pattern of skin damage under a microscope and help distinguish drug reactions from autoimmune blistering conditions

• Blood tests — including full blood count (to detect eosinophilia in DRESS), liver and renal function tests, and inflammatory markers; serial monitoring of organ function is essential in DRESS

• Patch testing — conducted only in specialist allergy or dermatology settings, deferred until at least six weeks after the reaction has resolved, and only in selected cases. It is not appropriate during the acute phase

• Drug provocation testing — this is contraindicated in patients with a history of SJS, TEN, DRESS, or other severe bullous drug reactions, due to the risk of triggering a life-threatening recurrence. It may be considered in specialist settings for milder, non-severe reactions only, following careful risk assessment

Treatment depends on the severity of the reaction. For mild reactions, withdrawing the offending drug is often sufficient, with supportive care such as emollients and antihistamines to manage symptoms.

More severe reactions require urgent hospital admission and specialist management, which may include:

• Early transfer to a specialist burns unit, dermatology unit, or intensive care setting, guided by SCORTEN scoring in SJS/TEN

• Intravenous fluids, nutritional support, and pain management — particularly in TEN, where loss of the skin barrier leads to significant fluid, protein, and electrolyte losses

• Wound care and infection prevention in specialist burns or dermatology units

• Immunomodulatory treatment — management is specialist-led. Evidence for intravenous immunoglobulin (IVIG) in SJS/TEN is mixed. Cyclosporine and etanercept are increasingly used in specialist centres based on emerging evidence and BAD guideline recommendations. Systemic corticosteroids may be considered in DRESS under specialist supervision. All such decisions should be made by the responsible specialist team

• Ophthalmology review if the eyes are affected, to prevent long-term complications including scarring and visual impairment; urogenital involvement should also be assessed and followed up

Following recovery, allergy documentation should follow the structured approach recommended in NICE CG183, recording the drug name, dose, route, timing of reaction, description and severity of the reaction, treatment required, and clear advice on future avoidance. A formal allergy alert should be added to the patient's NHS records, including their Summary Care Record, and the patient should be provided with a written allergy record or alert card to carry with them.

Reporting Medication Reactions to the MHRA

Suspected drug reactions causing blistering should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk, by patients, carers, or healthcare professionals, to support post-market drug safety surveillance.

In the UK, all suspected adverse drug reactions — including blisters from medication allergy — can and should be reported to the Medicines and Healthcare products Regulatory Agency (MHRA) via the Yellow Card scheme. This voluntary reporting system plays a vital role in post-market drug safety surveillance, helping regulators identify previously unrecognised risks and update prescribing guidance accordingly.

Reports can be submitted by:

• Patients and carers directly at yellowcard.mhra.gov.uk or via the MHRA Yellow Card app (available for iOS and Android)

• Healthcare professionals, including GPs, pharmacists, nurses, and hospital doctors

• Parents or guardians on behalf of children

When completing a Yellow Card report, it is helpful to include as much detail as possible: the name and dose of the medication, when it was started, when the reaction began, a description of the skin changes, and any treatment received. Even if you are uncertain whether the medication caused the reaction, reporting is still encouraged — the MHRA uses statistical analysis across large numbers of reports to detect patterns that individual cases cannot reveal.

Reporting adverse reactions is not just a regulatory formality — it is a meaningful contribution to patient safety. Yellow Card reports have contributed to important label changes and safety warnings for several medicines associated with serious skin reactions, including MHRA Drug Safety Updates on DPP-4 inhibitors and the risk of bullous pemphigoid. Patients who have experienced a significant drug reaction are encouraged to discuss reporting with their GP or pharmacist, and to ensure the reaction is formally documented in their medical records to protect their future care.

Frequently Asked Questions